Recently, Dr. Paula A. Munderi, Team Lead for Science, HIV Treatment and Paediatrics and Chief Scientific Officer at the Joint United Nations Programme on HIV/AIDS (UNAIDS), along with one accompanying delegate, visited Aidea Pharma at the request of Dr. Erasmus U. Morah, UNAIDS Country Director for China. The purpose was to understand progress in anti-HIV drug R&D and investments in Africa, aiming to advance global accessibility of HIV-related products.

The International Business team, together with heads of the Clinical Center and Production & Operations Center, received the visiting experts throughout the visit. During discussions, both teams focused on exchanging information about the clinical efficacy and product characteristics of Aidea Pharma's Class 1 innovative drug Ainuomiti Tablets and the Ainuovirine-based regimen. Comprehensive communication took place regarding the latest clinical research progress of Aidea Pharma's novel integrase inhibitor project ACC017 in the pipeline. The company also presented its work in African countries to promote local production and enhance drug accessibility. Following the company presentation, Dr. Munderi toured Aidea Pharma's formulation and active pharmaceutical ingredient (API) manufacturing facilities to understand production operations and the quality management system.

This visit marked Dr. Munderi's first on-site trip to conduct a field research on a Chinese innovative anti-HIV drug manufacturer. Dr. Munderi stated that "Aidea Pharma's product pipeline is highly forward-looking" and highly commended the company's international development strategy. As an international expert in paediatric HIV prevention and treatment, she expressed significant interest and expectations regarding the company's planned pediatric HIV drug development. Furthermore, she provided highly valuable guidance on advancing the internationalization of Aidea Pharma's innovative anti-HIV drugs.

Background on Dr. Paula Munderi

Dr. Munderi is an internationally renowned senior expert and leader in formulating HIV treatment strategies and pediatric HIV care within resource-limited settings in Africa. She possesses extensive clinical research experience, notably having led the globally influential DART trial (Development of Antiretroviral Therapy in Africa) in Africa.